Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
134 employees
Alloy Therapeutics: Democratizing drug discovery with innovative biotech platforms since 2017.
HQ
Founded
2017
Founded in 2017 and headquartered in Waltham, Massachusetts, Alloy Therapeutics is a biotechnology ecosystem company dedicated to democratizing access to foundational drug discovery platforms and services. Its core mission is to make medicine more accessible by providing innovative and royalty-free platforms like Alloy-Gx, which features immunocompetent transgenic mice for superior in vivo human antibody discovery. Alloy Therapeutics focuses on enabling robust biologics discovery through a collaborative community of partners.
Notable figures associated with Alloy Therapeutics include its founder and key investors who support its mission of transforming drug discovery. The company has achieved significant milestones, such as developing industry-leading platforms that enhance the efficiency and effectiveness of antibody discovery. By fostering a community-driven approach, Alloy Therapeutics has made a substantial impact on the biotech industry, contributing to the acceleration of new therapeutic developments.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Antibody Discovery, Biotech Platforms
Technology
Biotech
Tags
Biotech, SaaS
Model Types
Licensing, Platform
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Alloy Therapeutics founded?
Alloy Therapeutics was founded in 2017.
Where is Alloy Therapeutics's headquarters located?
Alloy Therapeutics's headquarters is located in Waltham, MA, US.
When was Alloy Therapeutics's last funding round?
Alloy Therapeutics's most recent funding round was for $42M (USD) in October 2022.
How many employees does Alloy Therapeutics have?
Alloy Therapeutics has 134 employees as of Feb 5, 2024.
How much has Alloy Therapeutics raised to-date?
As of July 05, 2023, Alloy Therapeutics has raised a total of $128.3M (USD) since Oct 3, 2022.
Add Comparison
Total Raised to Date
$128.3M
USD
Last Update Oct 3, 2022
Last Deal Details
$42M
USD
Oct 3, 2022
Series D
Current Employees
134
Last updated: Feb 5, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts